Angiotensin II in General Anesthesia

PHASE4CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 3, 2019

Primary Completion Date

March 21, 2023

Study Completion Date

March 21, 2023

Conditions
Hypertension
Interventions
DRUG

Angiotensin II

Participants in the ACE inhibitors, angiotensin-receptor blockers (ARBs), and Other Classes of Antihypertensive Agents who's systolic blood pressure (SBP) is less than 80% of the baseline reading is detected, will have Ang II initiated at 2 ng/kg/min through a peripheral IV. The infusion will be increased at the discretion of the clinical team based on the response of the patient until a SBP within 5% of the baseline SBP.

Trial Locations (1)

27157

Wake Forest Baptist Medical Center, Winston-Salem

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

National Institute on Aging (NIA)

NIH

lead

Wake Forest University Health Sciences

OTHER

NCT03733145 - Angiotensin II in General Anesthesia | Biotech Hunter | Biotech Hunter